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L-type calcium channels regulate ﬁlopodia stability
and cancer cell invasion downstream of integrin
signalling
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Mounting in vitro, in vivo and clinical evidence suggest an important role for ﬁlopodia in
driving cancer cell invasion. Using a high-throughput microscopic-based drug screen, we
identify FDA-approved calcium channel blockers (CCBs) as potent inhibitors of ﬁlopodia
formation in cancer cells. Unexpectedly, we discover that L-type calcium channels are
functional and frequently expressed in cancer cells suggesting a previously unappreciated role
for these channels during tumorigenesis. We further demonstrate that, at ﬁlopodia, L-type
calcium channels are activated by integrin inside-out signalling, integrin activation and Src.
Moreover, L-type calcium channels promote ﬁlopodia stability and maturation into talin-rich
adhesions through the spatially restricted regulation of calcium entry and subsequent
activation of the protease calpain-1. Altogether we uncover a novel and clinically relevant
signalling pathway that regulates ﬁlopodia formation in cancer cells and propose that cycles
of ﬁlopodia stabilization, followed by maturation into focal adhesions, directs cancer cell
migration and invasion.
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C
ell motility is involved at every stage of tumorigenesis
and contributes to primary tumour growth, cancer cell
dissemination and metastasis formation1,2. As metastasis
remains the leading cause of cancer-related morbidity in patients
with solid tumours3, there is an immediate need to gain a
more comprehensive understanding of the cellular structures and
signalling pathways that drive cancer cell migration. To migrate,
cells interact and sense the surrounding extracellular matrix
(ECM) via transmembrane adhesion receptors such as
integrins4–6. Integrin function is controlled by a conformational
switch between active and inactive states that determine ECM
ligand interaction and subsequent receptor signalling5. Integrin
activation from within the cell (integrin inside-out signalling) is
promoted by several mechanisms including the Rap1-RIAM-talin
pathway and leads to integrin-ECM engagement (integrin
outside-in signalling) and the recruitment and activation of a
large number of proteins including the oncogenic kinases focal
adhesion kinase (FAK) and Src to the integrin4,7.
Filopodia are actin-rich ﬁnger-like protrusions that extend
from the plasma membrane and have been implicated in cell
migration and invasion both in vitro and in vivo8. Filopodia are
assembled at the front of invading cancer cells8–10 and
ﬁlopodia-like structures promote cancer cell survival at
metastatic sites11,12. Several ﬁlopodia-inducing proteins such as
the molecular motor myosin-X (MYO10) or the actin-bundling
protein fascin promote cancer cell invasion both in vitro and in
mouse models and are associated with poor patient prognosis in
multiple carcinoma types8,13,14. Thus, interfering with ﬁlopodia
formation could be a viable strategy to inhibit cancer metastasis
in vivo. MYO10 is a homodimeric molecular motor which is
upregulated in breast cancer where its expression correlates
with mutant p53, poor prognosis and increased metastatic
potential13,15. Monomeric MYO10 is inactive and localizes to
the cytosol or to Rab7-positive vesicles16. MYO10 activation,
promoted by PI(3,4,5)P3, results in motor dimerization and
drives ﬁlopodia formation by transporting actin regulators, cell–
cell adhesion receptors and integrins to ﬁlopodia tips.
Here, we describe a novel druggable and clinically relevant
pathway regulating MYO10-positive ﬁlopodia formation and
stability. Unbiased high-throughput microscopy screens reveal
that L-type calcium channels, through regulation of calcium entry
at ﬁlopodia tips, drive ﬁlopodia stabilization. Unexpectedly,
L-type calcium channels are expressed and frequently altered in
many human cancers and contribute to cancer cell invasion by
regulating ﬁlopodia downstream of b1 integrin and Src activation.
Results
L-type calcium channel blockers inhibit ﬁlopodia formation.
To identify novel regulators of ﬁlopodia formation, cancer cells
expressing MYO10-GFP (to induce and visualize ﬁlopodia) were
treated with a library comprising over 500 compounds for 1 h
and imaged using high-throughput microscopy. The number
of MYO10-positive spots was automatically quantiﬁed to
determine the average number of ﬁlopodia per cell
(Supplementary Fig. 1A–D, see methods for details). From this
screen, several L-type calcium channel blockers (CCBs)
were identiﬁed as compounds that consistently inhibit ﬁlopodia
formation (Supplementary Figs 1D and 2A). In validation
experiments, four structurally distinct CCBs (amlodipine
besylate, felodipine, manidipine dichloride and cilnidipine)
were demonstrated to signiﬁcantly reduce the number of
MYO10-induced ﬁlopodia in breast cancer cells as efﬁciently as a
PI3K inhibitor (positive control to block MYO10 activity16),
whereas a treatment with zonisamide (inhibits t-type calcium
channels, voltage-gated sodium channels and carbonic
anhydrase) or bumetanide (inhibits the Naþ /Kþ /2Cl
cotransporter) failed to affect ﬁlopodia number (Fig. 1a).
Similar results were obtained in pancreatic cancer cells
following CCB treatment (Supplementary Fig. 2B). In addition,
overall inhibition of calcium entry into cells by EGTA-mediated
chelation of extracellular calcium dramatically reduced the
number of MYO10-induced ﬁlopodia (Supplementary Fig. 2C).
Together, these data indicate that calcium entry into cells
via L-type calcium channels positively regulates ﬁlopodia
formation in cancer cells.
L-type calcium channel expression in cancer cell lines.
The identiﬁcation of L-type calcium channels as regulators of
ﬁlopodia formation in cancer cells was unexpected as their
expression and activity is principally thought to be restricted
to excitable cells17,18. L-type calcium channels are composed
of multiple subunits (a1, a2d, b and g), of which the a1
subunit forms the core channel transporting calcium across the
plasma membrane and the other subunits form regulatory
components17,19. Four different genes (CACNA1C, CACNA1D,
CACNA1F and CACNA1S) encode the a1 subunit that is targeted
by CCBs. Interestingly, all four genes were found to be widely
expressed at variable levels across cancer cell lines20 (Fig. 1b)
regardless of their tissue of origin (Supplementary Fig. 3A–C).
Furthermore, we found that L-type calcium channels are
functional in cancer cell lines MDA-MB-231 and PDAC
p53R172H as treatment with a speciﬁc L-type calcium channel
activator (BAY K8644) triggered a rapid and transient increase
in intracellular calcium throughout the cell body (Fig. 1c;
Supplementary Fig. 3D; Supplementary Movies 1 and 2)
(3–4 fold increase at 1min post stimulation; detected with a
GFP-based calcium probe21) and at ﬁlopodia tips (Fig. 1d).
Importantly, calcium entry mediated by the L-type calcium
channel activator was inhibited in the presence of an L-type
calcium channel inhibitor (Fig. 1e).
L-type calcium channels are clinically relevant in cancer.
Analysis of public datasets using cBioPortal22,23 revealed that
L-type calcium channels are commonly altered in patient samples
of different cancer types (Supplementary Fig. 4A). In particular,
over 29% of patient samples in the Breast Invasive Carcinoma24
data set displayed alterations in CACNA1C, CACNA1D,
CACNA1F or CACNA1S and these alterations showed a
signiﬁcant association with unfavourable patient survival
(Supplementary Fig. 4B–D). Interestingly, the worst survival
rates were observed when alterations in CACNA1C, CACNA1D
and CACNA1S were analysed together (Supplementary Table 1).
Furthermore, while all four L-type calcium channel a1 subunits
are expressed at low levels in both healthy breast and breast
carcinoma samples (IST Online), CACNA1D is the most
commonly overexpressed a1 subunit in breast carcinoma while
CACNA1F is often downregulated (Supplementary Fig. 4E).
CACNA1D expression was also found to be upregulated in breast
cancer Oncomine data sets25 and was the most commonly
expressed L-type calcium channel a1 subunit in breast and
pancreatic cancer cell lines (Supplementary Fig. 3B,C). Taken
together, these data indicate that L-type calcium channels are
frequently altered in breast cancer samples and that alteration in
these genes may correlate with poor prognosis. The expression of
the individual L-type calcium channel a1 subunit in clinical
samples will require further studies using speciﬁc antibodies.
L-type calcium channels, cancer cell migration and invasion.
Filopodia support three-dimensional (3D) cell migration
and cancer invasion, particularly in cancers harbouring p53
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13297
2 NATURE COMMUNICATIONS | 7:13297 | DOI: 10.1038/ncomms13297 | www.nature.com/naturecommunications
mutations8,13. Importantly, similar to PI3K inhibition, CCB
treatment of p53 mutant breast and pancreatic cancer cells
(MDA-MB-231, P53R280K; PDAC, P53R172H; Su.86.86, P53G245S)
signiﬁcantly impaired cancer cell invasion (Fig. 2a–c), in a
concentration-dependent manner (Supplementary Fig. 5A,B). In
contrast, treatment with zonisamide or bumetanide had no effect
on cancer cell invasion (Fig. 2a,b). In addition, upregulation of
MYO10 expression lead to ﬁlopodia formation and was sufﬁcient
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to drive cancer cell invasion in non-invasive cell lines in a CCB
sensitive manner (Fig. 2d; Supplementary Fig. 5C,D). Functional
L-type calcium channels and PI3K activity were also important
for regulation of directionality during 3D cell migration on
cell-derived matrices (Fig. 2e). Thus, MYO10 expression
facilitates ﬁlopodia formation and invasion whereas inhibition
of L-type calcium channels using CCBs or inhibition of PI3K
impedes ﬁlopodia formation, directional cell migration and
cancer cell invasion.
Of the L-type calcium channel a1 subunits, expression of
CACNA1D, CACNA1S, but not CACNA1C, was detected in
MDA-MB-231 cells at the mRNA level (Fig. 3a; CACNA1F was
not tested as it appeared to be often downregulated in breast cancer
clinical samples). Importantly, individual silencing of CACNA1D
or CACNA1S gene expression using multiple siRNA oligos
(Supplementary Fig. 6A,B) decreased both ﬁlopodia formation
and cancer cell invasion (Fig. 3b,c), indicating that CACNA1D and
CACNA1S are likely to synergistically support ﬁlopodia formation
and cancer cell invasion in MDA-MB-231 cells. The cell biological
reagents to study L-type calcium channels are rather limited and
thus we were only able to analyse CACNA1D localization
(Supplementary Fig. 6B). Importantly, endogenous CACNA1D
localized with MYO10 at ﬁlopodia tips (Fig. 3d). In addition,
CACNA1D protein expression could be detected in all major breast
cancer subtypes (cancer type, positive expression; luminal, 3/6;
triple-negative, 7/8; Her2-positive, 4/4; healthy breast, 0/1) from a
set of breast carcinoma patient samples (Fig. 3e). Therefore, L-type
calcium channels, in particular CACNA1S and CACNA1D are
expressed in breast cancer and contribute to ﬁlopodia formation
and cancer cell invasion.
Calcium concentration and ﬁlopodia stability. Next we sought
to further study the relationship between calcium and ﬁlopodia
using two distinct approaches: a GFP-based calcium probe
(GCaMP6s) and a dye-based calcium indicator (Fluo4-AM). Live-
cell TIRF imaging of cells transiently co-expressing the GFP-based
calcium probe and MYO10-mCherry revealed that stable ﬁlopodia
(41min MYO10 spot lifetime) display higher levels of calcium
than unstable ﬁlopodia (o1min MYO10 spot lifetime) (Fig. 4a;
Supplementary Movies 3) while no difference in the ﬂuorescence
signal was observed between stable and unstable ﬁlopodia in cells
expressing GFP as a control (Fig. 4b). Correspondingly, Fluo4-AM
demonstrated higher intensity in stable ﬁlopodia (Supplementary
Fig. 6C). These data suggest that increased calcium levels at
ﬁlopodia tips correlates with ﬁlopodia stability. In line with this
notion, CCB-treated cells rapidly lost most of their calcium-
positive stable ﬁlopodia and displayed a higher proportion of
unstable ﬁlopodia compared with DMSO-treated cells (Fig. 4c,d;
Supplementary Movies 4–6). As a second read-out of ﬁlopodia
stability, the average velocity of MYO10 spots was measured and
was found to be much higher in CCB-treated cells indicative of
faster ﬁlopodia turnover following L-type calcium channel
inhibition (Fig. 4e). CCB treatment also decreased the number and
the stability of endogenous ﬁlopodia in both breast and pancreatic
cancer cell lines (see method for details; Fig. 4f,g; Supplementary
Fig. 6D). Taken together, calcium entry at ﬁlopodia via
L-type calcium channels contributes to ﬁlopodia stability as well as
ﬁlopodia formation.
Active integrins, ﬁlopodia and L-type calcium channels.
Integrins are one of the established cargos of MYO10 that are
transported to ﬁlopodia tips to mediate cell–ECM adhesion26. In
addition to the ﬁlopodia tip localization we observed active b1
integrins in the shafts of MYO10-positive ﬁlopodia (Fig. 5a).
Moreover, and congruent with a study describing Rap1-RIAM
localization to ﬁlopodia27, the integrin activator talin-1 was found
to localize with MYO10 at ﬁlopodia tips (Fig. 5b). In addition, the
Rap1/talin axis was important for ﬁlopodia formation as inhibition
of Rap1 (Fig. 5c; Supplementary Fig. 7A) or silencing of talin-1
expression (Fig. 5d; Supplementary Fig. 7B,C) signiﬁcantly reduced
ﬁlopodia number. Conversely, overexpression of a constitutively
active mutant of Rap1 (CA-Rap1, Fig. 5e; Supplementary Fig. S7D)
or of the FERM domain of talin-1 (talin head, Fig. 5f;
Supplementary Fig. 7E), known to promote integrin activity28,
signiﬁcantly increased ﬁlopodia formation. Given that Rap1 can be
activated by increases in calcium levels29, we tested whether L-type
calcium channels regulate ﬁlopodia formation through Rap1.
Interestingly, the expression of CA-Rap1 or talin head did not
restore ﬁlopodia numbers following CCB treatment (Fig. 5e,f),
suggesting that L-type calcium channels could act downstream of
the Rap1-RIAM-talin pathway. In addition, CCB treatment did not
inhibit overall integrin activity in cells suggesting that L-type
calcium channels do not promote ﬁlopodia by inducing integrin
activation (Supplementary Fig. 7F).
To further study the relationship between integrin activity,
ﬁlopodia number and calcium concentration at ﬁlopodia tips, cells
expressing a calcium probe and MYO10-mCherry were plated on
conformation-speciﬁc anti-b1 integrin antibodies which lock b1
integrin in either an active or inactive conformation30. Using this
system, b1 integrin activation signiﬁcantly increased ﬁlopodia
number as well as calcium levels at ﬁlopodia tips (Fig. 5g;
Supplementary Fig. 8). These integrin-mediated effects were fully
inhibited by CCB treatment (Fig. 5g; Supplementary Fig. 8), further
demonstrating that integrin activation acts upstream of L-type
calcium channels to regulate ﬁlopodia formation (Fig. 5h).
Integrins promote ﬁlopodia formation and stability via Src. As
the activation of FAK and Src are downstream events following
b1 integrin-ECM engagement, we next assessed a potential role
for these kinases in ﬁlopodia formation. The Src inhibitor
Figure 1 | L-type calcium channel blockers (CCBs) inhibit ﬁlopodia formation and L-type calcium channels are functional in cancer cells. (a) MDA-MB-
231 cells transiently expressing MYO10-GFP and adhering to ﬁbronectin (FN) were treated with various compounds (10mM) for 1 h, ﬁxed, stained for actin
and imaged on a TIRF microscope (scale bar, 20mm). The number of MYO10-positive ﬁlopodia was counted for each cell and displayed as a box plot
(three biological repeats, n4100 cells, ***P valueo8.3 10 17). (b) Relative expression of the four genes encoding the L-type calcium channel a1 subunit
across 676 commonly used cancer cell lines19. Gene expression read counts are displayed. The value 7.99 corresponds to non-detected (ND). Selected cell
lines are annotated. (c) MDA-MB-231 cells transiently expressing the calcium probe (pGP-CMV-GCaMP6s) and adhering to FN were treated with an
L-type calcium channel activator (BAY K8644; 1 mM) while being imaged on a TIRF microscope (63 objective). The relative increase in the intracellular
intensity of the calcium probe was measured at 1 and 10min post stimulation. Cell boundaries are indicated by dotted lines (three biological repeats, n¼ 74
cells; scale bar, 20mm). (d) MDA-MB-231 cells transiently expressing the calcium probe (pGP-CMV-GCaMP6s) and MYO10-mCherry were seeded on FN
and treated with an L-type calcium channel activator (BAY K8644; 1 mM) while being imaged on a TIRF microscope (100 objective; scale bar, 10 mm). The
inset shows a representative MYO10-positive ﬁlopodia tip delineated by a dotted line. ROI: region of interest. (e) MDA-MB-231 cells transiently expressing
the calcium probe (pGP-CMV-GCaMP6s) and adhering to FN were treated with an L-type calcium channel activator (BAY K8644; 1 mM) in combination
with DMSO or amlodipine besylate (1mM). The relative increase in the intracellular intensity of the calcium probe was measured at 1min (three biological
repeats, n421 cells; ***P valueo1.39 104). P values were calculated using Student’s t-test (unpaired, two-tailed, unequal variance).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13297
4 NATURE COMMUNICATIONS | 7:13297 | DOI: 10.1038/ncomms13297 | www.nature.com/naturecommunications
dasatinib decreased ﬁlopodia number in the original microscopy-
based drug screen (60% fewer ﬁlopodia than DMSO at 20 mM).
This result was validated using a small molecule inhibitor
of Src (PP2) which triggered a signiﬁcant loss in ﬁlopodia
compared with controls (PP3 and DMSO). In contrast, inhibition
of FAK had no effect on ﬁlopodia formation (Fig. 6a;
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Figure 2 | L-type calcium channels regulate ﬁlopodia formation and cancer cell invasion. (a) MDA-MB-231 cells were seeded into an inverted invasion
assay in the presence of various compounds (10mM) where indicated for 48 h. The relative invasion over 45 mm was quantiﬁed (n¼ three biological
repeats, ***P valueo1.3 10 5). (b) P53 / and P53R172H PDAC cells were seeded into an inverted invasion assay in the presence of various compounds
(10mM) for 4 days. The relative invasion over 45 mm was quantiﬁed (n¼ three biological repeats, ***P valueo4.1 10 8). (c) Su.86.86 pancreatic
carcinoma cells were seeded into an inverted invasion assay and allowed to invade for 4 days in the presence of various compounds (10mM). Relative
invasion over 45 mm was quantiﬁed (n¼ three biological repeats, ***P valueo9 10 3). (d) U2OS cells stably expressing either GFP or MYO10-GFP were
seeded into an inverted invasion assay and allowed to invade for 4 days in the presence of amlodipine besylate (10 mM) or DMSO. Relative invasion over
45mm was quantiﬁed (n¼ three biological repeats, ***P valueo4.05 106). (e) MDA-MB-231 cells were seeded on ﬁbroblast-generated cell
derived matrices (representative image is shown) in the presence of various compounds (10 mM), and cell migration was recorded over 24 h. Over 65 cells
were manually tracked for each condition and migration speed and directionality were measured (n¼ two biological repeats, scale bar, 200mm;
***P valueo2.6 10 5). P values were calculated using Student’s t-test (unpaired, two-tailed, unequal variance). All error bars represent s.e.m.
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Supplementary Fig. 9A). Similar to CCB treatment, PP2-mediated
inhibition of Src also promoted ﬁlopodia instability
(Supplementary Fig. 9B). Importantly, overexpression of a
constitutively-active mutant of Src (CA-Src) increased
ﬁlopodia number while overexpression of a dominant-negative
mutant of Src (DN-Src) inhibited ﬁlopodia formation (Fig. 6b;
Supplementary Fig. 9C). Immunoﬂuorescence analyses further
revealed active Src (pSrcY416) localization to ﬁlopodia (Fig. 6c)
suggesting a central role for Src in ﬁlopodia induction. These Src-
dependent effects appeared to be downstream of integrin sig-
nalling as treatment with a Src inhibitor (Fig. 6d) or over-
expression of DN-Src (Fig. 6e) signiﬁcantly reduced ﬁlopodia
number and calcium levels at ﬁlopodia tips in cells plated on the
anti-active b1 integrin antibody (Fig. 6d,e). Correspondingly,
overexpression of CA-Src was sufﬁcient to bypass the require-
ment for integrin activation and promoted ﬁlopodia formation
and calcium increase at ﬁlopodia tips in cells plated on the
anti-inactive b1 integrin antibody (Fig. 6e). Taken together, these
data indicate that Src activity plays a key role in ﬁlopodia
formation and stability downstream of integrin signalling.
Importantly, as CA-Src-induced ﬁlopodia remained sensitive to
CCB treatment (Fig. 6b) and as CCBs did not affect overall Src
activity (Supplementary Fig. 9D), these results indicate that
Src acts upstream of L-type calcium channels (Fig. 6f). However,
how Src promotes L-type calcium channel activation remains to
be determined.
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Increased MYO10 and Src protein expression and/or activity
have been reported independently in breast cancer and are
linked to metastasis and poor patient survival13,15,31. Given that
Src is critical for the formation of MYO10-positive ﬁlopodia, we
investigated a possible association between MYO10 and Src
protein levels and/or activity in patient samples. Using
cBioPortal, we determined that increased MYO10 levels strongly
correlates with increased Src mRNA levels in the Breast Invasive
Carcinoma data set (Log Odds ratio: 0.826; P value, o0.001).
Moreover, phosphoproteomic analyses indicated that patient
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samples with high MYO10 expression (130 patients out of 1,080;
12%) also exhibited higher Src activity (mean of alteration in
altered MYO10,  0.05; mean of alteration in unaltered group,
 0.23; P value, 1.408e 3; q value, 0.0162). Furthermore,
re-analysis of a tissue microarray comprising 1,212 samples
from a Finnish nationwide population-based breast cancer series
(FinProg cohort), previously stained for MYO10 (ref. 13) and
pSrcY416 (refs 13,32), revealed that MYO10 protein levels
correlate with Src activity in patient samples (Fig. 6g; Table 1).
Therefore, MYO10 expression correlates with both Src expression
and Src activity in breast cancer patient samples.
Calpain 1 and ﬁlopodia formation. Next we sought to identify
the calcium-regulated pathway(s) that is/are involved in
ﬁlopodia formation. Cells expressing MYO10-GFP were treated
with inhibitors targeting multiple calcium-regulated proteins and,
among these inhibitors, only the compound targeting calpain
activity signiﬁcantly diminished ﬁlopodia formation (Fig. 7a;
Supplementary Fig. 10A). More speciﬁcally, silencing of
calpain-1, and not calpain-2, expression decreased ﬁlopodia
number compared with control (Fig. 7b; Supplementary
Fig. 10B–E). In addition, calpain-1 and calpain-2 appeared to
have cooperative functions during the invasive process as
silencing of both calpain-1 and calpain-2 inhibited cell invasion
more efﬁciently than the individual depletion of either isoform
(Fig. 7c). Immunoﬂuorescence analyses revealed that calpain-1
localizes to ﬁlopodia (Fig. 7d) and ratiometric FRET analyses of
cells co-expressing a calpain sensor33 and MYO10-mCherry
demonstrated that calpains are active within ﬁlopodia (Fig. 7e;
controls related to the use of the calpain FRET probe are shown
in Supplementary Fig. 11). To assess whether calpains regulate
ﬁlopodia formation downstream of integrin activation, cells
expressing the calcium probe and MYO10-mCherry were
plated on anti-b1 integrin antibodies and treated with a
calpain inhibitor. Blocking calpain activity decreased ﬁlopodia
number but not calcium levels at the remaining ﬁlopodia tips in
cells plated on the anti-active b1 integrin antibody (Fig. 7f).
Altogether, these data indicate that calpain-1 regulates ﬁlopodia
formation downstream of integrin activation and calcium
accumulation at ﬁlopodia tips.
Filopodia stabilization leads to focal adhesion formation. The
importance of ﬁlopodia in the process of tumorigenesis has been
described in several cancers. However, the signiﬁcance of a
mechanism that could regulate ﬁlopodia stability during cell
migration has never been explored. CCB treatment only weakly
impacted focal adhesion dynamics as their overall lifetime
distribution was unaffected (Fig. 8a). CCB treatment appeared to
decrease both the assembly and disassembly rate of focal
adhesions as well as their maximal size (Fig. 8a). Using live-cell
TIRF imaging we found that talin-1-GFP localizes to both focal
adhesions and MYO10-positive ﬁlopodia and in many instances
was observed to move together with MYO10 spots along ﬁlopodia
shafts (Fig. 8b; Supplementary Movies 7). In stabilized ﬁlopodia,
both MYO10 and talin-1 were found to accumulate at ﬁlopodia
tips (Fig. 8b; Supplementary Movies 7). Subsequent advancement
of the plasma membrane coincided with MYO10 leaving the
growing talin-1-positive structure and the formation of new
MYO10-positive ﬁlopodia followed by accumulation of a
talin-positive patch resembling a classical focal adhesion.
These observations are in agreement with previous studies
demonstrating a role for ﬁlopodia in directing lamellipodia
formation in ﬁbroblasts34 and maturation of ﬁlopodial shaft
adhesions into focal adhesions upon lamellipodia advancement35.
Taken together, these data allow us to propose a model by which
ﬁlopodia formation and stabilization via an integrin/Src/L-type
calcium channel/calpain pathway, described here, contributes to
directional cell motility and cancer cell invasion (Fig. 8c).
Discussion
Here, we deﬁne the foundation of a druggable and clinically
relevant signalling pathway (Fig. 8c) that regulates ﬁlopodia
formation and stability in cancer cells. Notably, L-type calcium
channels are expressed in human cancer and targeting their
function with FDA-approved CCBs impairs ﬁlopodia formation
and blocks cancer cell invasion. Mechanistically, we establish a
link between a localized increase in calcium concentration at
ﬁlopodia tips, mediated by L-type calcium channels and ﬁlopodia
stability. Moreover, integrin inside-out activation and ligand
binding is indispensable for ﬁlopodia formation and appears to be
the ﬁrst critical step in this process following MYO10-dependent
delivery of integrins to ﬁlopodia tips. Subsequent steps require
integrin outside-in signalling to trigger Src activation and the
spatially restricted calcium entry at ﬁlopodia tips and the
activation of the calcium-regulated protease calpain-1. Finally,
we demonstrate that ﬁlopodia stabilization appears to precede
focal adhesion maturation and propose that cycles of ﬁlopodia
stabilization and focal adhesion maturation direct cell migration
and invasion.
The central position of L-type calcium channels in cancer cell
invasion was very unexpected as these voltage-gated channels
(expression and activity) are considered to be restricted to
excitable cells (neuronal and muscle cells). Nevertheless, several
studies report roles for L-type calcium channels in many other
cell types including ﬁbroblasts, kidney cells and endometrial and
prostate cancer cells36–38. In addition, analyses of available gene
expression data sets by us (this study) and others25 revealed a
wide expression of L-type calcium channels in many cancer cell
Figure 4 | Calcium at ﬁlopodia tips regulates ﬁlopodia stability. (a) MDA-MB-231 cells transiently expressing the calcium probe (pGP-CMV-GCaMP6s)
and MYO10-mCherry were plated on FN and imaged live using a TIRF microscope (1 picture every 5 s; scale bar, 20mm). The intensity of the calcium probe
at MYO10-positive ﬁlopodia tips was measured and compared between transient (o1min lifetime) and stable ﬁlopodia (41min lifetime) (n¼ 276
ﬁlopodia, three biological repeats, ***P valueo1.8 109). (b) MDA-MB-231 cells transiently expressing GFP and MYO10-mCherry were plated on FN and
imaged live using a TIRF microscope. The intensity of GFP at MYO10-positive ﬁlopodia tips was measured and compared between transient and stable
ﬁlopodia (n¼ 293 ﬁlopodia, three biological repeats). (c–e) MDA-MB-231 cells transiently expressing the calcium probe (pGP-CMV-GCaMP6s) and
MYO10-mCherry were plated on FN, treated with DMSO, felodipine or amlodipine besylate (10 mM) and imaged live using a TIRF microscope (1 picture
every 5 s; scale bar, 20mm). Representative images are shown (c). For each condition, MYO10-positive particles were automatically tracked and MYO10
spot lifetime (calculated as a percentage of the total number of ﬁlopodia generated per cell) (d) and average MYO10 spot velocity (e) were plotted
(see method for details; three biological repeats, n45,600 particles tracked in more than 16 cells, *P value¼0.015, ***P valueo2.98 10 5).
(f,g) MDA-MB-231 cells transiently expressing lifeact-GFP were plated on FN, treated with DMSO, felodipine or amlodipine besylate (10 mM), and imaged
live on a TIRF microscope. Movies were segmented and endogenous ﬁlopodia automatically identiﬁed using CellGeo51 (See method for details). Average
ﬁlopodia number per frame and per cell (f) and average ﬁlopodia lifetimes are displayed (g) (n416 cells, two biological repeats; *P value¼0.035,
***P valueo5.6 10 5). P values were calculated using Student’s t-test (unpaired, two-tailed, unequal variance). All error bars represent sem.
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lines and clinical samples. In particular, CACNA1D, which
localizes to ﬁlopodia tips and contributes to cancer cell invasion
in vitro (shown in this study), was found to be expressed in
patient samples in all major breast cancer subtypes.
The pathway delineated here as fundamental for ﬁlopodia
formation in cancer cells shares some similarities with
calcium-regulated processes identiﬁed in normal excitable cells.
In rat smooth muscle cells a5b1 integrin signalling has been
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described to promote CACNA1C-mediated calcium entry in
cells through Src phosphorylation of CACNA1C on Y2122
(refs 39–41). Hovewer, this phosphosite does not appear to be
conserved in the CACNA1D or CACNA1S isoforms identiﬁed
in our study as drivers of ﬁlopodia formation in cancer cells.
Whether integrins promote calcium entry through another, yet
unidentifed, Src phosphorylation site within CACNA1D or
CACNA1S or through another mechanism remains to be
determined. In neurons, calcium signalling, and in particular
L-type calcium channels and calpains, have been implicated in
ﬁlopodia formation and stability in growth cones42. However, our
discovery that non-excitable carcinoma cells have the potential to
employ these calcium-dependent processes in malignant invasion
was unanticipated. In particular, the relationship between calcium
concentration at ﬁlopodia tips and ﬁlopodia stability in cancer
cells is intriguing and appears to be important for directing the
migratory process during cancer cell invasion. In neurons,
the formation of dendritic ﬁlopodia is induced by small local
spikes in calcium concentration and is further stabilized by
accumulation of calcium in the newly formed ﬁlopodia43,44.
The parallels between ﬁlopodia formation and stability in neurons
and cancer cells could be another example of how cancer cells can
hijack physiological pathways to favourably promote the
metastatic process. It is noteworthy that inhibition of other
calcium-regulated proteins, associated with ﬁlopodia processes in
neurons, such as calcineurin and calcium-calmodulin-dependent
protein kinase II (refs 44,45) does not affect ﬁlopodia formation
in the MDA-MB-231 cancer cells used in this study. In the future,
it will be important to deﬁne the calpain-1 target/s involved in
ﬁlopodia stabilization in cancer cells.
L-type calcium channels are primarily activated by
depolarizing membrane potentials, raising important questions
on how these channels may be regulated in non-excitable cells.
Interestingly, L-type calcium channels can be activated by rather
weak depolarization events ( 55mV to positive)18 and cancer
cells have been reported to have depolarized membrane
potential compared with their healthy counterparts46. In
particular, MDA-MB-231 cells used in this study have a
resting membrane potential of around  20mV (ref. 47) which
may facilitate the activation of L-type calcium channels.
This would suggest that, in cancer cells with depolarized
membrane potential, L-type calcium channels could be
constitutively open, easily activated by small changes in
membrane potential or regulated by other cues (such as
activation of b1 integrin and/or Src signalling). Interestingly, a
recent study identiﬁed an interaction between b1 integrin
and one of the L-type calcium channel regulatory subunits
in Hela cells48, suggesting that, in addition to roles in L-type
calcium channel activation, b1 integrins could also dictate L-type
calcium channel sub-cellular localization.
Here, we present evidence that a pathway integral to ﬁlopodia
stability is clinically relevant in breast cancer. This pathway
involving integrin-driven stabilization of ﬁlopodia is potentially
relevant to other carcinomas, in particular cancers harbouring
p53 mutations. We have previously demonstrated that MYO10
levels correlate with gain of function p53 mutations in human
breast tumours, increased metastasis and poor prognosis.
Moreover, a gain of function mutation of p53 is sufﬁcient to
promote MYO10 expression13. These data are in conjunction
with the observation that p53-mutated cancer cells display a
high number of ﬁlopodia at the cell front during cell invasion9,10.
Another mechanism whereby mutant p53 drives cell invasion is
by promoting the co-recycling of a5b1 integrin and growth factor
receptors, such as EGFR, to the cell front6,49. Increased EGFR
signalling leads to the local activation of the PI3K/Akt pathway
which, in turn, promotes ﬁlopodia formation in a RhoA- and
FHOD3 formin-dependent manner9,10. Increased PI3K activity
downstream of EGFR signalling may also support ﬁlopodia
formation by promoting PIP3 production and MYO10
activation16. Furthermore, increased a5b1 integrin recycling to
the cell front and downstream signalling (shown in this study)
will ultimately lead to an upregulation of Src activity which will
enhance ﬁlopodia formation and stabilization.
Here, we propose that ﬁlopodia stability directs cell migration
and promotes cancer cell invasion. The ability of ﬁlopodia to
drive directional translocation of cells is probably linked to our
observation that adhesions formed at ﬁlopodia tips are followed
by formation of focal adhesions upon membrane advancement
and subsequently give rise to new ﬁlopodia which stem from the
newly formed adhesion. Given that ﬁlopodia are involved in
many biological processes ranging from the development of the
nervous system, to angiogenesis and cancer invasion, the
delineation of a pathway regulating the individual steps of
ﬁlopodia kinetics may have wide therapeutic implications. In
particular, as inhibition of L-type calcium channels blocks
cancer cell invasion in vitro, it will be important to focus further
studies on the potential of these channels as cancer targets using
pre-clinical cancer models.
Methods
Cell culture and transient transfection. MDA-MB-231 (triple-negative human
breast adenocarcinoma) cancer cells, mouse pancreatic ductal adenocarcinoma
cells (PDAC p53 / and PDAC p53R172H), human telomerase immortalized
foreskin ﬁbroblasts (TIFFs) and human bone osteosarcoma epithelial cells (U2OS)
were grown in DMEM (Sigma-Aldrich) supplemented with 10% FCS at 37 C and
5% CO2. The Su.86.86 human pancreatic cancer cell line was grown in DMEM
(Sigma-Aldrich) supplemented with 10% FCS at 37 C and 5% CO2.
Figure 5 | Integrin activation promotes ﬁlopodia formation and calcium entry at ﬁlopodia tips. (a,b) MDA-MB-231 cells transiently expressing
MYO10-mCherry were plated on FN, stained for active integrin (12G10 clone) (a) or talin-1 (b) and imaged using a TIRF microscope (scale bar, 20mm).
(c) MDA-MB-231 cells transiently expressing MYO10-GFP were plated on FN, treated with a Rap1 inhibitor (GGTI 298; 10mM) for 1 h, ﬁxed and the number
of MYO10-positive ﬁlopodia per cell was quantiﬁed (n4100 cells, three biological repeats, ***P valueo1.6 10 14). (d) MDA-MB-231 cells previously
silenced for talin-1 using two distinct siRNAs and transiently expressing MYO10-GFP were plated on FN for 2 h, ﬁxed and the number of MYO10-positive
ﬁlopodia per cell was quantiﬁed (n465 cells, three biological repeats, ***P valueo1.8 10 24). (e) MDA-MB-231 cells transiently expressing
MYO10-mCherry together with GFP or with a GFP-tagged constitutively active mutant of Rap1 (CA-Rap1) were plated on FN, treated with DMSO, felodipine
or amlodipine besylate (10mM), ﬁxed and the number of MYO10-positive ﬁlopodia per cell was quantiﬁed (n476 cells, three biological repeats;
***P valueo4.3 106). (f) MDA-MB-231 cells transiently expressing MYO10-mCherry together with GFP or with GFP-tagged talin head were plated on
FN, treated with DMSO, felodipine or amlodipine besylate (10 mM), ﬁxed and the number of MYO10-positive ﬁlopodia per cell was quantiﬁed (n477 cells,
three biological repeats; ***P valueo6.29 10 12). (g) MDA-MB-231 cells transiently expressing MYO10-mCherry and the calcium probe were plated on
conformation-speciﬁc anti-b1 integrin antibodies (anti-active b1 integrin, 12G10; anti-inactive b1 integrin, 4B4) for 2 h in the presence of DMSO, felodipine
or amlodipine besylate (10 mM). Representative images are displayed (scale bar, 20mm). For each condition, the number of MYO10-positive ﬁlopodia per
cell and the calcium probe intensity at ﬁlopodia tips were measured (three biological repeats, n460 cells; see Methods for details; ***P valueo1.2 104).
(h) Cartoon representing the sequence of events by which integrin inside-out signalling promotes calcium entry at ﬁlopodia tips, via L-type calcium
channels, and subsequent ﬁlopodia stability. P values were calculated using Student’s t-test (unpaired, two-tailed, unequal variance).
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The U2OS GFP and U2OS MYO10-GFP lines were generated by transfecting
U2OS cells using lipofectamine 2000 (ThermoFisher Scientiﬁc), according to
manufacturer’s instructions, and selected using Geneticin (ThermoFisher Scientiﬁc;
400mgml 1 ﬁnal concentration). MDA-MB-231 and Su.86.86 were provided by
ATCC. PDAC p53 / and PDAC p53R172H cells were a gift from Owen Sansom
(CRUK Beatson Institute, UK). TIFFs were donated by Jim Norman (CRUK
Beatson Institute, UK). U2OS cells were a gift from Lea Sistonen (University of
Turku, FI). All cells were tested for mycoplasma contamination.
Plasmids of interest were transfected using lipofectamine 3000 and the
P3000TM Enhancer Reagent (ThermoFisher scientiﬁc) according to
manufacturer’s instructions. The expression of proteins of interest was suppressed
using 100 nM siRNA and lipofectamine 3000 (ThermoFisher Scientiﬁc) according
D
M
SO
FA
K 
in
hi
bi
to
r
Co
nt
ro
l (P
P3
)
N
um
be
r o
f M
YO
10
-p
os
itiv
e
filo
po
di
a 
pe
r c
el
l
0
20
40
60
50
30
10
Sr
c 
in
hi
bi
to
r (
PP
2)
Mock D
N
-S
rc
 D
M
SO
CA-Src
Fe
lo
di
pi
ne
Am
lo
di
pi
ne
D
M
SO
Fe
lo
di
pi
ne
Am
lo
di
pi
ne
D
M
SO
0
20
40
60
50
30
10
N
um
be
r o
f M
YO
10
-p
os
itiv
e
filo
po
di
a 
pe
r c
el
l
a b
DMSO
CA-Src
Actin
MYO10-GFP
DMSO
DN-Src
Actin
MYO10-GFP
DMSO
Mock
Actin
MYO10-GFP
Amlodipine
CA-Src
Actin
MYO10-GFP
Anti-active
β1 integrin mAb
Anti-inactive
β1 integrin mAb
Src inhibitor (PP2) Control (PP3)
Src inhibitor (PP2) Control (PP3)
d
M
oc
k
D
N
-S
rc
CA
-S
rc
M
oc
k
D
N
-S
rc
CA
-S
rcC
al
ciu
m
 p
ro
be
 in
te
ns
ity
a
t fi
lo
po
di
a 
tip
s
0
1
2
D
M
SO
D
M
SO PP
2
PP
3C
al
ciu
m
 p
ro
be
 in
te
ns
ity
a
t fi
lo
po
di
a 
tip
s
0
1
2
D
M
SO
D
M
SO PP
2
PP
3
0
100
200
N
um
be
r o
f M
YO
10
-p
os
itiv
e
filo
po
di
a 
pe
r c
el
l
N
um
be
r o
f M
YO
10
-p
os
itiv
e
filo
po
di
a 
pe
r c
el
l
M
oc
k
D
N
-S
rc
CA
-S
rc
M
oc
k
D
N
-S
rc
CA
-S
rc
0
100
200
e
f g
MYO10-mCherry pSrc Y416 MYO10-mCherry
pSrc Y416
pS
RC
 Y
41
6
M
YO
10
c
Patient 1
Inactive
integrins
Active
integrins
Talin
Rap1
Ca2+
L-type Ca2+
channels
?
Src
?
Filopodia stability
Anti-active β1 integrin mAb
Ca
lci
um
 p
ro
be
M
YO
10
-m
Ch
er
ry
Ca
lci
um
 p
ro
be
***
***
***
***
***
***
***
*** ***
***
***
***
***
***
***
Patient 2
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13297 ARTICLE
NATURE COMMUNICATIONS | 7:13297 | DOI: 10.1038/ncomms13297 | www.nature.com/naturecommunications 11
to manufacturer’s instructions. SiRNA used as control (siCTRL) was Allstars
negative control siRNA (Qiagen, Cat. No. 1027281). In addition, the SMARTpool
ON-TARGETplus CACNA1C siRNA (Dharmacon, Cat. No. L-006123-00-0005)
was used as an additional control for all experiments where SMARTpool siRNA
were used. The siRNA targeting calpain-1 #1 and calpain-2 were custom-made
(Qiagen; Calpain-1 #1: 50-AAGCTAGTGTTCGTGCACTCT-30 ; Calpain-2:
50-AAACCAGAGCTTCCAGGAAAA-30). The siRNA targeting calpain-1 #2 was
purchased from ThermoFisher Scientiﬁc (Cat. No. 4390824; siRNA ID, s490). The
siRNAs targeting talin-1 were purchased from Qiagen (siTalin1#1, Hs_TLN1_2
FlexiTube siRNA, Cat. No. SI00086968; siTalin1#2, Hs_TLN1_3 FlexiTube siRNA,
Cat. No. SI00086975). The siRNAs targeting CACNA1D were siCACNA1D #1
(Dharmacon, SMARTpool ON-TARGETplus, Cat. No. L-006124-00-0005)
and siCACNA1D #2 (Qiagen, Hs_CACNA1D_3 FlexiTube siRNA, Cat. No.
SI00337211). SiRNA targeting CACNA1S were siCACNA1S #1 (Dharmacon,
SMARTpool ON-TARGETplus, Cat. No. L-006130-00-0005) and siCACNA1S
#2 (Qiagen, Hs_CACNA1S_3 FlexiTube siRNA, Cat. No. SI00001260).
Antibodies and other reagents. Mouse anti-human b1 integrin 12G10 (ab30394;
10mgml 1) and rat anti-human b1 integrin 9EG7 (553715; 1:100 for IF) mono-
clonal antibodies, which recognize integrin receptors with high afﬁnity for ligand
(termed ‘active’), were purchased from Abcam and BD Biosciences, respectively.
Mouse anti-human b1 integrin monoclonal 4B4 (10 mgml 1), which recognizes
receptors with low afﬁnity for ligand (termed ‘inactive’), was obtained from
Beckman Coulter. Mouse monoclonal antibodies raised against human
talin-1 (clone 8d4, Cat. No. T3287; 1:100 for IF), human CACNA1D (used for
immunocytochemistry, 1/100; clone S48A-9; Cat. No. SAB5200022), b-actin
(Clone AC-15, Cat. No. A1978) and FLAG (Clone M2; Cat. No. F3165; 1:200 for
IF) were purchased from Sigma. Mouse monoclonal antibodies raised against a
tubulin (clone 12G10; 1:1000 for WB) and phosphotyrosine (Clone PY20; 610000;
1:1000 for WB) were purchased from the Hybridoma Bank and BD Biosciences,
respectively. Rabbit polyclonal antibodies used in this study were anti-human
calpain-1 (Abcam, ab39170, 1:1000 for WB), anti-human calpain-2 (Abcam,
ab39165, 1:1000 for WB), anti-human CACNA1D (used for immunohistochem-
istry, 1/600; Sigma, HPA020215), anti-Phospho-Src (Y416; Cell signalling, 2101;
1:1000 for WB and 1:100 for IF), anti-human Src (Cell signalling, 2108; 1:1000 for
WB) and anti-human MYO10 (Novus Biologicals, 22430002; 1:1000 for WB).
Active Rap1 (CA-Rap1; pEGFP-C3-Rap1Q63E) was a gift from Buzz Baum (UCL,
UK). CAAX-GFP was a gift from Gregory Giannone (Bordeaux University,
France). The following plasmids were provided by Addgene (Addgene plasmid
number; gift from): pCMV-calpainsensor (36182; Isabelle Richard), p3XFlag-
CAPN1 (60941; Yi Zhang), pGP-CMV-GCaMP6s (40753, Douglas Kim), pLNCX
chick Src E378G (13661; Joan Brugge), pCMV5 mouse Src K295R Y527F (13657;
Joan Brugge and Peter Howley), mEmerald-Paxillin-22 (54219; Michael Davidson).
Bovine plasma ﬁbronectin (FN) was purchased from Merck (Cat. No. 341631).
Alexa Fluor 488 and Alexa Fluor 568 phalloidin were provided by ThermoFisher
Scientiﬁc. Compounds used in this study were dissolved in sterile DMSO (Sigma)
and are detailed in Supplementary Table 2.
MYO10 drug screen. Cells stably expressing MYO10-GFP were plated at low
density in 384-well plates (Corning) and treated with an FDA-approved drug
library composed of 522 compounds (Selleckchem) at two different concentrations
(20 and 40mM) for 1 h. Cells were then ﬁxed, DAPI stained and imaged using an
Olympus ScanR Screening Station. Images were analysed using Fiji ImageJ
packaged with Michael Schmid’s Find Maxima plugin. Brieﬂy, images were opened
and, after background subtraction and normalization, MYO10 spots were
automatically detected using Michael Schmid’s ‘Find maxima’ plugin. As inactive
MYO10 is known to accumulate in rab7 vesicles16, to obtain an accurate number of
ﬁlopodia-speciﬁc MYO10 spots, intracellular MYO10 spots were excluded from the
analysis. Intracellular MYO10 spots were automatically ﬁltered by analysing the
intensity of the area surrounding each spots (intracellular MYO10 spots have
surrounding areas of high intensity). The remaining spots were counted and
divided by the number of nuclei. The ImageJ macro used to do the quantiﬁcation is
provided as Supplementary Software 1.
Immunoﬂuorescence microscopy. Unless otherwise stated, images were acquired
on a TIRF microscope (Zeiss Laser-TIRF 3 Imaging System, Carl Zeiss) using a
63 (numerical aperture (NA) 1.46 Oil, alpha Plan-Apochromat, DIC) or a
100 (NA 1.46 Oil, alpha Plan-Apochromat, DIC) objective. Images were
acquired on an EMCCD camera (Hamamatsu ImageEM C9100-13; Chip size
512 512; Hamamatsu Photonics K.K., Hamamatsu City, Japan) controlled by the
Zen software (Zen 2012 Blue Edition Systems; Carl Zeiss).
For TIRF microscopy experiments, cells were plated for 2 h on glass-bottom
dishes (MatTek Corporation) precoated with 10 mgml 1 of bovine plasma FN
overnight at 4 C. Cells were then ﬁxed in 4% (wt/vol) paraformaldehyde (PFA) for
20min, washed with PBS and permeabilized with PBS containing 0.5% (vol/vol)
Triton X-100 for 3min. Cells were then washed with PBS, blocked using a solution
of 1M glycine for 30min and incubated with primary antibodies (1/100) for 30min
at room temperature, washed with PBS and incubated for a further 30min with the
appropriate secondary antibodies (1/400) at room temperature. After washing,
glass-bottom dishes were stored in PBS in the dark at 4 C before analysis.
Filopodia formation assays on ﬁbronectin. Cells expressing human MYO10-GFP
were plated for 2 h in full medium (1h þ 1 h treatment when stimulated with a
compound of interest) on glass-bottom dishes (MatTek Corporation) precoated with
10mgml 1 of FN. Cells were then ﬁxed using PFA, washed with PBS, permeabilized
and stained using phalloidin. Images were acquired on a TIRF microscope using a
63 objective and the number of ﬁlopodia per cell was manually scored.
Filopodia formation assays on anti-b1 integrin antibodies. Cells expressing
bovineMYO10-mCherry and the GFP-based calcium probe (pGP-CMV-GCaMP6s)
were plated for 2 h in serum-free medium on glass-bottom dishes (MatTek
Corporation) precoated with 10mgml 1 of conformation-speciﬁc anti-b1 integrin
antibodies (active, 12G10; inactive, 4B4), overnight at 4 C, as previously described50.
Cells were then ﬁxed using PFA, washed with PBS, blocked using a solution of 1M
glycine and imaged on a TIRF microscope using a 100 objective. The
quantiﬁcation of the number of MYO10 spots per cell as well as the intensity of the
calcium probe at ﬁlopodia tips was performed semi-automatically using the custom
made ImageJ plugin provided as a supplementary ﬁle (Supplementary Software 2).
This plugin requires a stack composed of two images (MYO10 and a counter-stain
that allows delimitation of the cell edge). Brieﬂy, after background subtraction, the
cell edges were delimited semi-automatically using the colour threshold option. To
obtain a mask of the cell that does not contain ﬁlopodia, three pixel erosion cycles
followed by three pixel dilatation cycles were performed. Next, MYO10 spots were
detected semi-automatically using a pass band ﬁlter followed by the identiﬁcation of
local maxima to create a mask containing all MYO10 spots. The cell mask and the
mask containing the MYO10 spots were then compared and only the MYO10 spots
located outside the cells were quantiﬁed. In addition, the integrated density of the
calcium probe at MYO10 spots located outside the cell mask was measured. This
plugin also calculates other parameters including the area and the min and max grey
values of each spot, the minimal distance between each spot and the cell edge
(ﬁlopodia length) and the number of MYO10 intracellular spots.
Live-cell ﬂuorescence microscopy. For optimal image resolution, culture
medium was replaced with Ham’s F-12 (Gibco) containing 25mM HEPES for all
live-cell imaging experiments. For BAY K8644 stimulation experiments, cells
expressing the GFP-based calcium probe (pGP-CMV-GCaMP6s) were plated for at
Figure 6 | Src regulates ﬁlopodia formation and calcium entry at ﬁlopodia tips. (a) MDA-MB-231 cells transiently expressing MYO10-GFP were plated
on FN and treated for 1 h with DMSO, a FAK inhibitor (FAK inhibitor 14; 10mM), a Src inhibitor (PP2; 10mM) or a negative control for the Src inhibitor (PP3;
10mM). The number of MYO10-positive ﬁlopodia per cell was counted (three biological repeats, n466 cells; ***P valueo2.1 10 25). (b) MDA-MB-231
cells transiently expressing MYO10-GFP together with PCDNA3, or with a constitutively active mutant of Src (CA-Src, Src E378G) or with a dominant
negative mutant of Src (DN-Src, Src K295R Y527F) were plated on FN and treated with DMSO, felodipine or amlodipine besylate (10 mM). Representative
images are displayed (scale bar, 20mm). For each condition, the number of MYO10-positive ﬁlopodia per cell was quantiﬁed (three biological repeats,
n487 cells; ***P valueo2.5 10 21). (c) MDA-MB-231 cells transiently expressing MYO10-mCherry were plated on FN, stained for active Src (pSrcY416)
and imaged using a TIRF microscope (scale bar, 20mm). (d) MDA-MB-231 cells transiently expressing MYO10-mCherry and the calcium probe were plated
on conformation-speciﬁc anti-b1 integrin antibodies in the presence of DMSO, PP2 or PP3 (10 mM). Representative images are displayed (scale bar, 20mm).
The number of MYO10-positive ﬁlopodia per cell and the calcium probe intensity at ﬁlopodia tips were measured (three biological repeats, n461 cells;
***P valueo2.4 104). (e) MDA-MB-231 cells transiently expressing MYO10-mCherry and the calcium probe together with PCDNA3, or with CA-Src or
with DN-Src, were plated on conformation-speciﬁc anti-b1 integrin antibodies. The number of MYO10-positive ﬁlopodia per cell and the calcium probe
intensity at ﬁlopodia tips were measured (n450 cells, three biological repeats, ***P valueo1.3 104). (f) Cartoon displaying the sequence of events by
which integrin inside-out signalling leads to ﬁlopodia stabilization. (g) Representative images of a breast cancer TMA that was previously stained for
MYO10 and pSrcY416 illustrating that high MYO10 levels correlate with high Src activity in patient samples (scale bar, 100mm). P values were calculated
using Student’s t-test (unpaired, two-tailed, unequal variance).
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least 2 h on glass-bottom dishes (MatTek Corporation) precoated with 10 mgml 1
of FN before the start of the treatment. Cells were then imaged every 10 s, on a
TIRF microscope using either a 63 or 100 objective, at 37 C and using
multi-position capabilities. BAY K8644 stimulation (1 mM ﬁnal concentration) was
performed live during imaging and maximal increases in calcium were observed
after 1min stimulation. Quantiﬁcation of the changes in calcium concentration,
based on the calcium probe intensity, was performed using ImageJ. GCaMP6s
imaging: Laser line, 488 (2.8% power); external ﬁlter, 490–550 nm; exposure
time, 42ms; EM gain, 101; large TIRF angles were used to ensure that only the
cell–substrate interface was imaged. Deﬁnite focus was used to ensure that no
variation occurred in the z position.
To study the relationship between ﬁlopodia stability and calcium concentration,
cells were either co-expressing MYO10-mCherry and the GFP-based calcium
probe (pGP-CMV-GCaMP6s) or expressing MYO10-mCherry and loaded with the
calcium indicator dye Fluo-4 using the Fluo-4 Direct Calcium Assay Kit
(ThermoFisher Scientiﬁc; F10471). When the GFP-based calcium probe was
used cells were plated on FN for at least 2 h before the start of imaging. When
Fluo-4 was used, cells were plated for 1 h on FN, before being loaded with the
calcium dye according to the manufacturer’s instructions (30min at
37 Cþ 30min at room temperature). Cells were imaged within 1 h from the end of
Fluo-4 loading as this dye rapidly disappears from the TIRF plane and accumulates
in intracellular bodies. For both the GFP-based calcium probe and the Fluo-4
approaches, cells were imaged live, every 5 s at 37 C, on a TIRF microscope using a
100 objective. GCaMP6s imaging: Laser line, 488 (5% power); external ﬁlter,
490550 nm; exposure time, 85ms; EM gain, 363; large TIRF angles were used to
ensure that only the cell-substrate interface was imaged. Single position and
deﬁnite focus were used to ensure that no variation occurred in the z position.
Fluo-4 imaging: Laser line, 488 (5% power); external ﬁlter, 490–550 nm; exposure
time, 95ms; EM gain, 66; large TIRF angles were used to ensure that only the
cell–substrate interface was imaged. Single position and deﬁnite focus were used to
ensure that no variation occurred in the z position. The calcium probe/reporter
intensity at stable (41min lifetime) and unstable ﬁlopodia (o1min lifetime) was
measured using ImageJ. Brieﬂy, for each cell, ﬁlopodia tips were detected,
thresholded and their lifetime measured using the MYO10-mCherry channel.
The integrated intensity of the calcium probe was measured at each ﬁlopodia tip.
The measurements were then averaged in function of the ﬁlopodia lifetime and the
ratio between calcium probe intensity at stable and unstable ﬁlopodia was
calculated. The same experiment and analysis was performed in cells expressing
GFP and MYO10-mCherry as a negative control using the same settings as for the
GCaMP6s imaging.
To study the role of L-type calcium channels and Src in ﬁlopodia stability, cells
expressing MYO10-mCherry and the GFP-based calcium probe were plated
for at least 2 h on FN in the presence of the compound of interest (or DMSO)
before the start of live imaging (pictures taken every 5 s at 37 C, on a TIRF
microscope using a 100 objective). All MYO10 spots were then identiﬁed and
tracked using the ImageJ plugin Particle Tracker 2D and 3D packaged within the
Mosaic suite51. The velocity of MYO10 spots was then analysed using the ImageJ
plugin chemotaxis tool.
To analyse the number and dynamics of endogenous ﬁlopodia, cells were
transfected with lifeact-GFP and plated for at least 2 h on FN in the presence of the
compound of interest (or DMSO) before being imaged live, every 10 s at 37 C on a
TIRF microscope using a 100 objective. Videos were then automatically analysed
using the Matlab application CellGeo52.
To analyse the dynamics of focal adhesions, cells were transfected with
mEmerald-Paxillin and plated for at least 6 h on FN in the presence of amlodipine
besylate (or DMSO) before being imaged live on a TIRF microscope, at 37 C, in
presence of 5% CO2. Images were acquired every minute for at least 3 h, using a
63 (NA 1.46 Oil, alpha Plan-Apochromat, DIC) objective and an internal
Optovar (1.6 magniﬁcation). Acquired videos were pre-processed using ImageJ
and in particular, the contrast was adjusted, a smooth ﬁlter was applied and the
frames were aligned using the ‘rigid body algorithm’. Focal adhesion dynamics
were then analysed by uploading the videos to the focal adhesion analysis
server (FAAS; http://faas.bme.unc.edu/)53 using the following settings: detection
threshold, 2; Min Adhesion Size, 2 pixels; Min FA, Phase Length (10min);
Min FAAI Ratio, 3.
FRETanalysis of calpain activity. MDA-MB-231 cells transiently expressing CFP
(donor only), YFP (acceptor only), CFP and YFP (free donor and free acceptor) or
pCMV-calpainsensor (CFP and YFP linked by a calpain cleavage site; low
FRET¼ higher calpain activity) were plated on FN-coated glass-bottom dishes for
2 h at 37 C. Cells were then ﬁxed in 4% (wt/vol) PFA for 10min, washed with PBS
and blocked using a solution of 1M glycine for 30min. Cells were then imaged
using a confocal microscope (LSM780, Zeiss). The ZEN imaging software was used
to generate and export the Fc images with intensities converted from the FRET
index calculated for each pixel using the Youvan method. To validate the FRET
approach, FRET signals (Fc) were measured in cells previously silenced for
calpain 1 and 2 and in cells treated with the calcium ionophore Calcimycin
(A23187; calpain activator). To measure the calpain activity in ﬁlopodia, cells were
co-transfected with pCMV-calpainsensor and with MYO10-mCherry.
SDS–PAGE and quantitative western blotting. Protein extracts were separated
under denaturing conditions by SDS–PAGE and transferred to nitrocellulose
membranes. Membranes were blocked for 1 h at room temperature with blocking
buffer (LI-COR Biosciences) and then incubated overnight at 4 C with the appro-
priate primary antibody diluted in blocking buffer. Membranes were washed with
PBS and then incubated with the appropriate ﬂuorophore-conjugated secondary
antibody diluted 1:5,000 in blocking buffer for 30min. Membranes were washed in
the dark and then scanned using an Odyssey infrared imaging system (LI-COR
Biosciences). Band intensity was determined by digital densitometric analysis using
Odyssey software. Uncropped blots are available in Supplementary Fig. 12.
Cell migration on cell-derived matrices. Cell-derived matrices were generated as
previously described54. Brieﬂy, TIFFs were seeded at a density of 50,000 cells per ml
in a 24-well plate. When conﬂuent, cells were cultured for a further 10 days, with
medium being changed every 48 h to complete medium supplemented with
50mgml 1 ascorbic acid (Sigma-Aldrich) to ensure collagen cross-linking. Mature
matrices were then denuded of cells using lysis buffer (PBS containing 20mM
NH4OH and 0.5 % (vol/vol) Triton X-100). Following PBS washes, matrices were
incubated with 10mgml 1 DNase I (Roche) at 37 C for 30min. Matrices were then
stored in PBS containing 1% (vol/vol) penicillin/streptomycin at 4 C before use.
For cell migration analyses, MDA-MB-231 cells were seeded at a density of
5,000 cells per ml on cell-derived matrices and allowed to spread for 4 h. Cells were
then ﬁlmed using an inverted wideﬁeld microscope (AxioCam MRm camera, EL
Plan-Neoﬂuar 10 /0.5 NA objective (Carl Zeiss)) equipped with a heated
chamber (37 C) and CO2 controller (5%). Images were collected every 10min, and
ten movies were generated for each condition. To assess cell migration, the speed
and directionality of cells were measured using the Manual Tracking plug-in of
ImageJ. Cell tracking was performed over a 24 h time period. Results were
computed and analysed by the ImageJ plug-in Chemotaxis Tool.
Inverted invasion assay. Inverted invasion assays were modiﬁed from those
described previously9,55. In brief, 200 ml of collagen I (concentration 5 mgml 1;
PureCol EZ Gel, Advanced BioMatrix) supplemented with 25 mgml 1 FN was
allowed to polymerize in inserts (8mm ThinCert; Greiner bio-one) for 1 h at 37 C.
Inserts were then inverted, and cells were seeded directly onto the opposite face of
the ﬁlter. Transwell inserts were placed in serum-free medium, and medium
supplemented with 10% FCS was placed on top of the matrix, providing a
chemotactic serum gradient. Where appropriate, compounds were added to both
the lower and upper chambers. Migrating cells were ﬁxed 48–72 h after seeding
using 4% PFA for 2 h, permeabilized in 0.5 % (vol/vol) Triton-X 100 for 30min at
room temperature, and stained overnight at 4 C using Alexa Fluor 488 phalloidin.
Plugs were then washed three times using PBS and imaged on a confocal
microscope (LSM510; Zeiss) controlled using Zen2009 Systems Software
(Carl Zeiss). Serial optical sections were captured every 15 mm using a
20 objective lens (NA 0.50 air, Plan-neoﬂuar). Individual confocal images are
presented in sequence with increasing penetrance from left to right. Invasion was
quantiﬁed using the area calculator plugin in ImageJ, measuring the ﬂuorescence
intensity of cells invading 45 mm or more and expressing this as a percentage of the
ﬂuorescence intensity of all cells within the plug.
Table 1 | MYO10 staining and pSrc Y416 cytoplasm staining
in FinProg crosstabulation.
MYO10 score pSrc Y416 cytoplasm score Total
0 1 2
0
Count 135 2 0 137
% with MYO10 98.54% 1.45% 0% 100%
1
Count 747 137 16 900
% with MYO10 83% 15.22% 1.77% 100%
2
Count 123 46 6 175
% with MYO10 70.28% 26.28% 3.42% 100%
Total
Count 1005 185 22 1212
% with MYO10 82.9% 15.26% 1.81% 100%
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Figure 7 | Calpain-1 regulates ﬁlopodia formation. (a) MDA-MB-231 cells transiently expressing MYO10-GFP were plated on FN, treated for 1 h with
various inhibitors (10mM with the exception of cyclosporin A, enzastaurin and sotrastaurin used at 1 mM) directed against calcium-regulated pathways,
ﬁxed and imaged on a TIRF microscope. The number of MYO10-positive ﬁlopodia per cell was counted (n486 cells, three biological repeats;
***P valueo2.4 10 24). (b) MDA-MB-231 cells previously silenced for calpain-1, using two distinct siRNA, and/or for calpain-2, and transiently
expressing MYO10-GFP, were plated on FN for 2 h, ﬁxed and the number of MYO10-positive ﬁlopodia per cell was quantiﬁed (n462 cells, three biological
repeats; ***P valueo4.01 10 11). (c) MDA-MB-231 cells previously silenced for calpain-1 and/or for calpain-2 were seeded into an inverted invasion
assay and allowed to invade for 48 h. Relative invasion over 45 mm was quantiﬁed (three biological repeats, *** P valueo1.2 104). (d) MDA-MB-231
cells transiently expressing MYO10-mCherry and FLAG-calpain-1 were plated on FN for 2 h, stained with an anti-FLAG antibody and imaged on a TIRF
microscope (scale bar, 20mm). (e) MDA-MB-231 cells transiently expressing MYO10-mCherry and a calpain FRET probe (pCMV-calpainsensor; CFP and
YFP linked by a calpain cleavage site, low FRET¼higher calpain activity) were plated on FN and imaged on a confocal microscope (scale bar, 5mm). The
averaged FRET ratios measured in ﬁlopodia and in the cell body are displayed (three biological repeats, cell body n¼ 23, ﬁlopodia n¼ 236;
***P valueo8.9 10 15). Controls relative to this FRET experiment are presented in Supplementary Fig. 11. (f) MDA-MB-231 cells transiently expressing
MYO10-mCherry and the calcium probe were plated on conformation-speciﬁc anti-b1 integrin antibodies (as in Fig. 5g) in the presence of DMSO or a
calpain inhibitor (10 mM) (scale bar, 20mm). The number of MYO10-positive ﬁlopodia per cell and the calcium probe intensity at ﬁlopodia tips were
measured (n474 cells, three biological repeats; **P valueo4.3 10 3, ***P valueo3.06 10 6). P values were calculated using Student’s t-test
(unpaired, two-tailed, unequal variance).
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Quantitative RT-PCR. Total RNA extracted using the NucleoSpin RNA Kit
(Macherey-Nagel) was reverse transcribed into cDNA using the high-capacity
cDNA reverse transcription kit (Applied Biosystems) according to the
manufacturer’s instructions. The RT-PCR reactions were performed using prede-
signed single tube TaqMan gene expression assays (GAPDH: Hs03929097_g1;
CACNA1D: Hs00167753_m1; CACNA1C: Hs00167681_m1; CACNA1F:
0 s
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Figure 8 | Filopodia stabilization directs cell migration. (a) MDA-MB-231 cells transiently expressing mEmerald-Paxillin were plated on FN and imaged
live using a TIRF microscope (1 picture every 1min over 3 h; scale bar, 20mm) in the presence of DMSO or amlodipine besylate (10 mM). Focal adhesion
properties were analysed using the focal adhesion analysis server53 (three biological repeats; over 33 movies per condition analysed; adhesion lifetime and
maximal area, n4112,000 adhesions analysed; assembly rate, n46100 adhesions analysed; disassembly rate, n47,200 adhesions analysed, ***P value
o1.73 10 50). P values were calculated using Student’s t-test (unpaired, two-tailed, unequal variance). (b) MDA-MB-231 cells transiently expressing
talin-1-GFP and MYO10-mCherry were plated on FN and imaged live using a TIRF microscope (1 picture every 5 s; scale bar, 20mm). Images of the region of
interest (yellow squares) at the time point of interest are displayed on the right. Yellow arrows highlight MYO10-positive ﬁlopodia that precede mature
focal adhesions. (c) Cartoon representing the sequence of events, identiﬁed in this study, leading to ﬁlopodia stabilization and ultimately focal adhesion
formation. Brieﬂy, unstable ﬁlopodia are extended from the plasma membrane to tether the surrounding environment. These ﬁlopodia display low calcium
concentration at their tips. Molecular motors such as MYO10 transport integrins and other adhesion receptors to ﬁlopodia tips. Upon integrin activation,
the kinase Src, directly or indirectly, promotes L-type calcium channel activity resulting in increased calcium concentration at ﬁlopodia tips. Higher calcium
concentration at ﬁlopodia tips promotes calpain-1 activation and ﬁlopodia stabilization. Ultimately, upon plasma membrane advancement, adhesions
initiated at ﬁlopodium tips/shafts precede mature classical focal adhesion.
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Hs00913730_m1; CACNA1S: Hs00163885_m1) and were analysed with the
7900HT fast RT-PCR System (Applied Biosystems). Data were studied using RQ
Manager Software (Applied Biosystems).
Clinical sample analyses. Analyses of publicly available data sets were performed
using IST online (MediSapiens Ltd; http://ist.medisapiens.com/) or cBioPortal
(http://www.cbioportal.org/index.do). Interrogation of the Breast Invasive
Carcinoma (TCGA, Cell 2015)24 which contains 1,105 samples was performed
using cBioPortal. The genomic proﬁles selected were mutations, putative
copy-number alterations from GISTIC and mRNA expression data (mRNA
Expression z-Scores (RNA Seq V2 RSEM)). Survival analyses were performed
using the Survival tab and the co-expression analyses were performed using the
Co-expression or the Enrichment tabs.
Potential correlation between MYO10 and pSrcY416 levels in patient samples
was assessed in the FinProg series, a Finnish nationwide breast cancer cohort.
Patient and sample inclusion criteria for FinProg are described in detail
elsewhere56. The FinProg series (1,212 samples) was previously stained for pSrcY416
and MYO10 expression as described earlier13,32. From these data a potential
association between the expression groups was assessed using the w2-test.
Permission to use patient samples for research purposes was provided by the
Ministry of Social Affairs and Health, Finland (permission 123/08/97).
CACNA1D staining of patients samples. The use of breast cancer tissue samples
was performed with approval from the ethical committee of Turku University
Hospital (149/6/2002) and Auria Biobank (AB15-9859) and accordingly informed
consent was obtained from all human participants. Breast tissue material
was prepared according to standard histology practice, that is, ﬁxed in buffered
formalin (pH 7.0) and embedded into parafﬁn blocks. TMAs were prepared by
collecting tissue cores (4mm in diameter) from the representative tumour area of
each patient. Tissue sections (3 mm thick) were cut and stained with anti-CAC-
NA1D antibody (1/600) using Lab Vision Autostainer 480 (Thermo-Fisher Sci-
entiﬁc, Fremont, CA, USA) and detected with PowerVisionþ polymer kit,
according to standard protocols (DPVBþ 110HRP; Immunovision Technologies,
Vision Biosystems, Norwell, MA, USA), using diaminobenzidine as the
chromogen.
Statistical analysis. Statistical analyses were performed when appropriate, and
P values indicated by an asterisk in the ﬁgure legends. Unless otherwise indicated,
the Student’s t-test was used (unpaired, two-tailed, unequal variance). Frequency
tables were analysed by using two-tailed w2-test.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and from the authors on request.
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